Subscribe to RSS
DOI: 10.1055/s-0029-1225287
© Georg Thieme Verlag KG Stuttgart · New York
Rheumatologie 2009
Rheumatology 2009Publication History
Publication Date:
10 June 2009 (online)
Was ist neu ?
-
Kardiovaskuläres Risiko bei rheumatoider Arthritis: Hauptfaktoren Krankheitsaktivität und Nikotinabusus.
-
Biologika: Hemmung von IL-6 genauso effektiv wie Hemmung von TNF.
-
Kortikosteroide: Abendliche Einnahme einer zeitverzögerten Galenik erreicht endogenes Steroidtief am frühen Morgen.
-
„Small Molecules”: Klinische Wirksamkeit weiterhin nicht erreicht.
-
Kollagenosen und Vaskulitiden: Konventionelle Immunsuppressiva gewinnen gegenüber Cyclophosphamid an Bedeutung.
-
Bildgebung: Gelenkultraschall und Nagelfalzkapillaroskopie diagnostischer und Facharztstandard.
Literatur
- 1 Alten R E, Zerbini C, Jeka S. et al . Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann Rheum Dis. , epub ahead of print
- 2 Backhaus M. Ultrasound and structural changes in inflammatory arthritis: synovitis and tenosynovitis. Ann N Y Acad Sci. 2009; 1154 139-151
- 3 Bertsias G, Ioannidis J P, Boletis J. et al . EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008; 67 195-205
- 4 Braun J, Kästner P, Flaxenberg P. et al . Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008; 58 73-81
- 5 Buttgereit F, Doering G, Schaeffler A. et al . Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008; 371 205-214
- 6 Emery P, Keystone E, Tony H P. et al . IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008; 67 1516-1523
- 7 Gottlieb A, Menter A, Mendelsohn A. et al . Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009; 373 633-640
- 8 Ingegnoli F, Boracchi P, Gualtierotti R. et al . Prognostic model based on nailfold capillaroscopy for identifying Raynaud’s phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (prognostic index for nailfold capillaroscopic examination). Arthritis Rheum. 2008; 58 2174-2182
- 9 Kain R, Exner M, Brandes R. et al . Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med. 2008; 14 1088-1096
- 10 Kay J, Matteson E L, Dasgupta B. et al . Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008; 58 964-975
- 11 Keystone E, Heijde D, Mason D. et al . Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008; 58 3319-3329
- 12 Klareskog L, Catrina A I, Paget S. Rheumatoid Arthritis. Lancet. 2009; 373 659-672
- 13 Kowal-Bielecka O, Landewé R, Avouac J. et al . EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009; 68 620-628
- 14 Leombruno J P, Einarson T R, Keystone E C. The safety of anti-tumor necrosis factor treatments in rheumatoid arthritis: meta and exposure adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2008; epub ahead of print
- 15 Mukhtyar C, Guillevin L, Cid M C. et al . EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009; 68 310-317
- 16 Mukhtyar C, Guillevin L, Cid M C. et al . EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009; 68 318-323
- 17 Schumacher H R, Becker M A, Wortmann R L. et al . Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008; 59 1540-1548
- 18 Smolen J S, Beaulieu A, Rubbert-Roth A. et al . Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371 987-997
- 19 van Staa T P, Smeeth L, Persson I, Parkinson J, Leufkens H G. What is the harm-benefit ratio of Cox-2 inhibitors?. Int J Epidemiol. 2008; 37 405-413
Prof. Dr. med. Ulf Müller-Ladner
Lehrstuhl für Innere Medizin mit Schwerpunkt
Rheumatologie der Justus-Liebig Universität Giessen, Abteilung
für Rheumatologie und klinische Immunologie, Kerckhoff-Klinik
Bad Nauheim
Benekestrasse 2–8
61231
Bad Nauheim
Phone: 06032/9962101
Fax: 06032/9962104
Email: u.mueller-ladner@kerckhoff-klinik.de